Article Text

Download PDFPDF
Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding National Health and Medical Research Council (Early Career Fellowship, Postdoctoral Fellowship, Senior Research Fellowship).

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

  • i Global estimates of the prevalence of hepatitis C virus in the population vary greatly. Mathers et al reported midpoint country estimates ranging from 0.02% (India and Cambodia) to 5.21% (Azerbaijan). In Western Europe (with the exception of the Netherlands, where there is very little reported injecting drug use) the prevalence ranged from 0.13% (Greece) to 0.83% (Italy). In countries like the USA, Canada, Australia and New Zealand, estimated prevalences are close to 1%.41

  • ii As outlined earlier, estimated HCV prevalences in the national populations of PWID vary greatly, ranging from 10% to 97%.6 ,7